Answers are grounded in this paper and cite their sources.
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. This retrospective cross-sectional study aimed to characterise concomitant medication use and explore its associations with GBE utilisation and patient-reported experiences using data from the pharmacoepidemiological database PhytoVIS. Methods: In a study cohort of 184 patients, we examined co-medication use, associations with GBE treatment habits (intake frequency, treatment duration, and daily dosage) and patient-reported perception of effectiveness and tolerability using descriptive statistics and exploratory non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients reporting adverse events (AEs) rated as significant, and patients with GABS scores >2. Results: Overall, 64.7% of patients used co-medication. Cardiovascular drugs were used by 27.7% of all patients, followed by antidiabetic drugs (11.4%) and analgesics/anti-inflammatory drugs (9.8%). While no statistically significant correlation with treatment duration was observed, our exploratory, unadjusted analysis indicated a weak negative correlation between the number of co-medications and daily GBE doses (Spearman’s ρ = −0.156, 95% CI [−0.299, −0.006], p = 0.037). Three patients reported AEs rated as significant during GBE intake. However, patients generally rated perceived effectiveness and tolerability favourably across co-medication groups. Four GBE users had calculated cumulative GABS scores >2 and rated the perceived effectiveness of GBE as moderate to very good without reporting any adverse events. Conclusion: Co-medication was common in GBE users, and patients rated the effectiveness and tolerability favourably across co-medication groups. The weak correlation between a higher number of co-medications and lower GBE doses should be interpreted cautiously as a hypothesis-generating finding. Overall, these findings highlight the relevance of considering concomitant medication when examining GBE utilisation, particularly in the context of self-medication.
No takes yet. Share an insight, caveat, or question.
Scholl et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: